- Short report
- Open Access
- Open Peer Review
Almond supplementation reduces serum uric acid in coronary artery disease patients: a randomized controlled trial
© The Author(s). 2016
- Received: 28 March 2016
- Accepted: 2 August 2016
- Published: 19 August 2016
Elevated serum uric acid (UA), a biomarker of renal insufficiency, is also an independent prognostic marker for morbidity in coronary artery disease (CAD) and poses serious health risks. This study reports the effect of almond consumption on UA in CAD patients.
A randomized controlled clinical trial was conducted with three groups: no-intervention (NI), Pakistani almonds (PA) or American almonds (AA). Patients were recruited from the Cardiology Clinics, Aga Khan University Hospital. Two follow-ups were scheduled at week-6 and week-12. 150 patients were randomly divided in three groups (50 per group). NI was not given almonds, whereas the PA and AA were given Pakistani and American almond varieties (10 g/day), respectively; with instruction to soak overnight and eat before breakfast.
Almonds supplementation significantly reduced (p < 0.05) serum UA among groups, and over time. At week-6, UA concentrations were -13 to -16 % less in PA and AA; at week-12 the concentrations were -14 to -18 % less, compared to NI. Systolic and diastolic blood pressure and body weights of the participants remained fairly constant among all the groups.
Almonds (10 g/day), eaten before breakfast, reduces serum UA in CAD patients. Prevention of hyperuricemia can confer protection from kidney and vascular damage and if extrapolated for general population, dietary almonds can offer grander health benefit. Trial is registered at Australian New Zealand Clinical trial registry as ACTRN12614000036617.
- Coronary artery disease
- Soaked almonds
- Low dose
There has been considerable increase in global prevalence of hyperuricemia, in the past few years, backed by western dietary patterns. Where higher serum uric acid (UA) frequently indicates renal insufficiency , it may also be associated with coronary artery disease (CAD) , and deliberated as a prognostic marker for morbidity and mortality, independent of other risk factors . Even in patients with no history of heart disease or stroke, elevated UA was associated with higher risk of myocardial infarction or stroke . An increase in serum UA by 1 mg/dL contributes to 12 % increase in risk of CAD death . This association is believed to be stronger in women than men . But there are also some indications where, in middle-aged men, hyperuricemia served as a risk factor for cardiovascular and all-cause mortality .
UA is shown to possess anti-oxidant potential , which undermines its causative role in chronic diseases. Yet, its establishment as a comorbid risk marker is backed by recent meta-analysis  and systemic review  showing significant correlation between hyperuricemia and CAD. Further signifying its role for cardiovascular health, are the studies where anti-hypertensive and/or lipid-neutralizing therapies limited UA production, thereby reducing CAD mortality [9, 10].
Almonds are among the nuts approved by Food and Drug Administration – United States to have the potential of reducing CVD risk . The lipid-neutralizing properties, among others, have been extensively elaborated . Dietary supplementation of almonds is shown to prevent hyperuricemia in a cardiovascular disease rat model . This study inspects the UA-reducing potential of almond supplementation in CAD patients.
Hundred and fifty CAD patients were recruited from Cardiology Clinic at The Aga Khan University Hospital, Karachi. The eligibility criteria and trial logistics have previously been defined in detail, following the CONSORT guidelines . Briefly, patients consuming nuts on regular basis (>15 g/d; three days/week) or those having nut allergies were excluded. Informed consent was obtained. Using block randomization, patients were assigned any of the following three groups: No Intervention (NI); Intervention with Pakistani almonds (PA) or American almonds (AA).
Approval was obtained from Ethical Review Committee of The Aga Khan University, Karachi, Pakistan (Application ID: 2230-Med-ERC-12), and the trial was registered at Australian New Zealand Clinical Trial Registry (ID: ACTRN12614000036617).
Baseline blood was drawn and vitals (body weight, blood pressure etc.) were recorded. Participants of NI were instructed not to consume any nuts, specifically almonds, during their enrollment in trial; whereas participants of PA and AA were given almonds (10 g/day), with the instruction to consume in a traditional way (i.e. soak overnight, peel and eat before breakfast in the morning). Diaries, to record almond consumption, were provided. Compliance was monitored through regular phone calls (twice per week). Follow-up visits were scheduled at week-6 and week-12 (±3 days), at which blood samples were collected and vitals were recorded. Participants of NI received almonds after the completion of trial.
Pakistani almonds, namely Talwar, grown in Balochistan – Pakistan; and imported American almonds, locally available at Utility stores in Karachi, were used. Serum concentration of uric acid (UA) was measured on Roche Cobass c-111 automated analyzer using commercially available kit (Uric acid kit no. 4657608190).
Data were analyzed on SPSS version 17.0 and Graphpad Prism, and results are presented as means ± SEM. Two-way repeated measures ANOVA was used to compare means of groups followed by Bonferroni post-tests. For categorical data, chi-square test was used to compare differences between groups. P-value < 0.05 was considered statistically significant (95 % Confidence interval).
Baseline characteristics of CAD patients randomized into no-intervention, Pakistani almond or American almond groups
Body weight, kg
Blood Pressure, mmHg
Serum Uric Acid, mg/dL
Blood pressure and serum uric acid concentrations of CAD patients randomized into no-intervention (NI), Pakistani almonds (PA) and American Almonds (AA) groups, at week-6 and week 12
n = 25
n = 9
n = 27
n = 11
n = 33
n = 8
Uric Acid, mg/dL
Serum UA concentrations were similar at baseline (Table 1), in all the groups (p > 0.05). In a male-to-male and female-to-female comparison, the data in Table 2 show that in PA group, at week-6, males had -15 % and females had -12 % lower UA than those in NI (p < 0.05). At week-12, male and female participants of PA had -17 and -16 % lower concentrations, respectively, those in NI (p < 0.05). Table 2 also shows that, at week-6, serum UA in male and female participants of AA were -17 and -19 % less than in NI (p < 0.05). At week-12, UA was further reduced up to -20 and -21 % in males and females, respectively, in AA.
Figure 1b compares UA concentrations of baseline and intervention. At week-12, there was negligible (-3 and -2 %) drop in males and females of NI, while the drop in PA and AA was significant (-16 and -14 % in males and females of PA and -18 % in both males and females of AA; p < 0.05).
To the best of our knowledge, this is the first almond-intervention study on CAD patients reporting UA reduction. Previously, in rat model, dietary almonds prevented high-fat diet-induced hyperuricemia, followed by reduced nitric oxide (NO) production via endothelial NO synthase (eNOS) inhibition resulting in improved vascular function of isolated aorta . So, from results in CAD patients, we can also infer probable vascular protection.
Serum UA may be considered as a biomarker for vascular function . Anticipated pathways of UA-induced vascular dysfunction  include, but are not limited to: pro-oxidative affect, whereby UA decomposes and generates free radicals; pro-inflammatory affect via association with biomarkers like interleukins (IL-1, IL-6, IL-10, IL-18), tumor necrosis factor (TNF-α) and C-reactive proteins (CRP); endogenous stimulation of innate immunity; changing expression of endothelin-1; promoting angiotensin-II production; inducing smooth muscle cell proliferation; and direct reaction with, and depletion of NO.
Almond supplementation is shown to influence some of these parameters. Although, Jenkins et al. report no effect of almonds on CRP, BP or pulmonary NO ; Rajaram et al.  observed significant reduction in CRP. Two studies in diabetic patients [19, 20], report a drop in CRP accompanied by anti-inflammation via IL-6 reduction; while Liu et al. , also reports decrease in TNF-α by dietary almonds. Bhardwaj et al. , also demonstrated drop in CRP, accompanied by improved flow-mediated dilatation, indicating improved endothelial function. But more recently, Chen et al.  reported no effect of almond supplementation on vascular function, CRP, TNF-α and even the lipid profile of CAD patients in a randomized cross-over clinical trial. This may be due to the drug therapy which could mimic the effect of intervention. Decrease in vascular cell adhesion molecules was observe, which may indicate improvement in vascular function. Trials longer than four to six weeks may be able to offer detectible improvements in vascular function of CAD patients.
Almonds are rich in L-arginine, which is a precursor of NO. Supplementation of L-synthetic arginine reverses hyperuricemia-induced hypertension in rats . However, BP of participants in our trial remained fairly constant during twelve weeks. Reason being, almost all CAD patients were on anti-hypertensive medications, and baseline BP was within normal ranges.
The precise underling mechanisms of almonds action on serum uric acid remains to be explored. Certain limitations of our trial include the following. The inclusion criteria included only those CAD patients, who had optimal LDL-C and sub-optimal HDL-C. This may not truly represent the CAD population in general. Sample size was calculated for observable improvements in serum HDL.
Almond supplementation can provide holistic benefits to CAD patients. Previous clinical studies have almonds’ potential in ameliorating dyslipidemia, the current investigation adds to its vasculo-protective effects, by presenting prominent reduction in serum uric acid.
AA, American almonds; BP, blood pressure; CAD, coronary artery disease; CVD, cardiovascular diseases; NI, no intervention; NO, nitric oxide; PA, Pakistani almonds; UA, uric acid
This study was supported by the Higher Education Commission through Indigenous PhD scholarship grant. The Higher Education Commission had no role in the design, analysis or writing of this article.
Availability of data and materials
The data supporting the conclusions of this article are included within the article (table and figure).
AHG designed and guided research (project conception, development of overall research plan, and study oversight). HJ conducted research (hands-on conduct of the experiments and data collection) and analyzed the data and drafted the manuscript. FATS was the primary Cardiologist involved in dealing with patients. FA helped in designing of the clinical trial and statistical analysis. JA, SG and MM were involved in patients’ recruitment and maintaining follow-up visits, blood collection, processing and preservation. AHG, FATS and JA helped in refining the manuscript. All authors have read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
The written informed consent signed by all the participants, also included the consent for publication.
Ethical approval and consent to participate
This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human patients were approved by the Ethics Review Committee, Aga Khan University (Application ID: 2230-Med-ERC-12). Written informed consent (in both languages i.e. English and Urdu) was obtained from all patients.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2407–13.View ArticlePubMedPubMed CentralGoogle Scholar
- Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: atherosclerosis risk in communities (ARIC) study. Ann Epidemiol. 2000;10:136–43.View ArticlePubMedGoogle Scholar
- Isik T, Ayhan E, Ergelen M, Uyarel H. Uric acid: a novel prognostic marker for cardiovascular disease. Int J Cardiol. 2012;156:328–9.View ArticlePubMedGoogle Scholar
- Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke the Rotterdam study. Stroke. 2006;37:1503–7.View ArticlePubMedGoogle Scholar
- Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62:170–80.Google Scholar
- Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA. 2000;283:2404–10.View ArticlePubMedGoogle Scholar
- Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148:131–9.View ArticlePubMedGoogle Scholar
- Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med. 2005;2:236.View ArticleGoogle Scholar
- Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, Tziomalos K, Ganotakis ES, Elisaf M. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome a subgroup analysis of the GREek atorvastatin and coronary heart disease evaluation (GREACE) study. Nephrol Dial Transplant. 2007;22:118–27.View ArticlePubMedGoogle Scholar
- Song Q, et al. Impact of allopurinol on heart function, endothelial function and indexes of inflammation in patients with acute myocardial infarction. China Pharmacy. 2006;24:018.Google Scholar
- Ternus M, et al. Qualified health claim for nuts and heart disease prevention: development of consumer-friendly language. Nutr Today. 2006;41:62–6.View ArticleGoogle Scholar
- Berryman CE, Preston AG, Karmally W, Deckelbaum RJ, Kris-Etherton PM. Effects of almond consumption on the reduction of LDL-cholesterol: a discussion of potential mechanisms and future research directions. Nutr Rev. 2011;69:171–85.View ArticlePubMedGoogle Scholar
- Jamshed H, Gilani AH. Almonds inhibit dyslipidemia and vascular dysfunction in rats through multiple pathways. J Nutr. 2014;144:1768–74.View ArticlePubMedGoogle Scholar
- Jamshed H, Sultan FA, Iqbal R, Gilani AH. Dietary almonds increase serum HDL cholesterol in coronary artery disease patients in a randomized controlled trial. J Nutr. 2015;145:2287–92.View ArticlePubMedGoogle Scholar
- Jamshed H, Arslan J, Gilani AH. Cholesterol-cholate-butterfat diet offers multi-organ dysfunction in rats. Lipids Health Dis. 2014;13:194.View ArticlePubMedPubMed CentralGoogle Scholar
- Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–90.View ArticlePubMedGoogle Scholar
- Jenkins DJ, Kendall CW, Marchie A, Parker TL, Connelly PW, Qian W, Haight JS, Faulkner D, Vidgen E, Lapsley KG, Spiller GA. Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein (a), homocysteine, and pulmonary nitric oxide a randomized, controlled, crossover trial. Circulation. 2002;106:1327–32.View ArticlePubMedGoogle Scholar
- Rajaram S, Connell KM, Joan S. Effect of almond-enriched high-monounsaturated fat diet on selected markers of inflammation: a randomised, controlled, crossover study. Br J Nutr. 2010;103:907–12.View ArticlePubMedGoogle Scholar
- Sweazea KL, Johnston CS, Ricklefs KD, Petersen KN. Almond supplementation in the absence of dietary advice significantly reduces C-reactive protein in subjects with type 2 diabetes. J Funct Foods. 2014;10:252–9.View ArticleGoogle Scholar
- Liu JF, et al. The effect of almonds on inflammation and oxidative stress in Chinese patients with type 2 diabetes mellitus: a randomized crossover controlled feeding trial. Eur J Nutr. 2013;52:927–35.View ArticlePubMedGoogle Scholar
- Bhardwaj R, Manivannan S, Gharib W, Warden B, Hobbs G, Jain A. Acute effects of diets rich in almonds and walnuts on endothelial function in humans. Circulation. 2012;126:A14738.Google Scholar
- Chen CY, Holbrook M, Duess MA, Dohadwala MM, Hamburg NM, Asztalos BF, Milbury PE, Blumberg JB, Vita JA. Effect of almond consumption on vascular function in patients with coronary artery disease: a randomized, controlled, cross-over trial. Nutr J. 2015;14:61.View ArticlePubMedPubMed CentralGoogle Scholar
- Sánchez-Lozada LG, Tapia E, López-Molina R, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J, Franco M. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol-Renal Physiol. 2007;292:1238–44.View ArticleGoogle Scholar